Technologies

Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma’s technology and Sanofi’s technology and tumor targets Innate Pharma eligible for up to €400m in...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory...

“Site-specific conjugation by BTG improves the therapeutic index of ADC in vivo ” “Versatility of Site-Specific Conjugation based on Bacterial Transglutaminase” Innate Pharma SA (the “Company” -...

New site-specific conjugation technology for homogenous antibody-drug conjugates (ADCs) Provides further opportunities for portfolio expansion and partnering Innate Pharma SA (the “Company” - Euronext...